The stock has a 36-month beta value of 1.01. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ELVN is 21.40M, and at present, short sellers hold a 19.78% of that float. On April 11, 2024, the average trading volume of ELVN was 159.05K shares.
ELVN) stock’s latest price update
Enliven Therapeutics Inc (NASDAQ: ELVN)’s stock price has plunge by 19.48relation to previous closing price of 19.82. Nevertheless, the company has seen a 27.31% surge in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-02-27 that BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference in Boston, MA, on Tuesday, March 5, 2024, at 12:50 p.m. ET.
ELVN’s Market Performance
Enliven Therapeutics Inc (ELVN) has seen a 27.31% rise in stock performance for the week, with a 85.73% gain in the past month and a 87.34% surge in the past quarter. The volatility ratio for the week is 10.07%, and the volatility levels for the past 30 days are at 10.79% for ELVN. The simple moving average for the past 20 days is 37.31% for ELVN’s stock, with a 56.95% simple moving average for the past 200 days.
Analysts’ Opinion of ELVN
Many brokerage firms have already submitted their reports for ELVN stocks, with Mizuho repeating the rating for ELVN by listing it as a “Buy.” The predicted price for ELVN in the upcoming period, according to Mizuho is $34 based on the research report published on April 09, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ELVN reach a price target of $27. The rating they have provided for ELVN stocks is “Buy” according to the report published on March 29th, 2023.
ELVN Trading at 43.82% from the 50-Day Moving Average
After a stumble in the market that brought ELVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.63% of loss for the given period.
Volatility was left at 10.79%, however, over the last 30 days, the volatility rate increased by 10.07%, as shares surge +94.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +46.81% upper at present.
During the last 5 trading sessions, ELVN rose by +28.49%, which changed the moving average for the period of 200-days by +21.63% in comparison to the 20-day moving average, which settled at $17.83. In addition, Enliven Therapeutics Inc saw 71.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELVN starting from Patel Anish, who sale 4,875 shares at the price of $18.60 back on Apr 08 ’24. After this action, Patel Anish now owns 2,597 shares of Enliven Therapeutics Inc, valued at $90,687 using the latest closing price.
Ballal Rahul D., the Director of Enliven Therapeutics Inc, sale 3,485 shares at $19.15 during a trade that took place back on Apr 04 ’24, which means that Ballal Rahul D. is holding 22,341 shares at $66,729 based on the most recent closing price.
Stock Fundamentals for ELVN
The total capital return value is set at -0.34. Equity return is now at value -42.61, with -39.35 for asset returns.
Based on Enliven Therapeutics Inc (ELVN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -182.89. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 49.31.
Currently, EBITDA for the company is -83.23 million with net debt to EBITDA at 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.28.
Conclusion
To sum up, Enliven Therapeutics Inc (ELVN) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
